Skip to main content

Table 4 Association between low-dose aspirin usage in the year prior to diagnosis and cancer-specific and all-cause mortality in lung cancer patients

From: Low-dose aspirin and survival from lung cancer: a population-based cohort study

Medication usage after diagnosis Cancer-specific deaths All-cause mortality All patients Person years Cancer-specific mortality All-cause mortality
Unadjusted P Adjusteda P Unadjusted P Adjusteda P
      HR 95 % CI   HR 95 % CI   HR 95 % CI   HR 95 % CI  
Number of patients      [n = 13,433]   [n = 13,388]   [n = 13,433]   [n = 13,388]  
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent   1.00 Referent   1.00 Referent   1.00 Referent  
Aspirin user 3,055 3,468 3,869 3,331 1.07 1.02, 1.11 <0.01 1.00 0.95, 1.05 0.91 1.10 1.05, 1.14 <0.001 1.01 0.96, 1.06 0.77
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent   1.00 Referent   1.00 1.00   1.00 Referent  
Aspirin user 1 to 11 prescriptions 2,367 2,690 2,998 2,608 1.06 1.01, 1.11 0.02 0.99 0.94, 1.04 0.75 1.09 1.04, 1.14 <0.001 1.00 0.95, 1.05 0.90
Aspirin user ≥ 12 prescriptions 688 778 871 723 1.09 1.01, 1.18 0.03 1.02 0.94, 1.11 0.64 1.11 1.04, 1.20 <0.01 1.02 0.95, 1.11 0.57
Aspirin non-user 7,577 8,369 9,564 9,154 1.00 Referent   1.00 Referent   1.00 1.00   1.00 Referent  
Aspirin user 1–365 tablets 2,214 2,508 2,804 2,436 1.06 1.01, 1.12 0.01 1.00 0.95, 1.06 0.97 1.09 1.04, 1.14 <0.001 1.01 0.96, 1.06 0.70
Aspirin user ≥366 tablets 841 960 1,065 895 1.07 1.00, 1.15 0.06 0.98 0.91, 1.06 0.70 1.11 1.04, 1.18 <0.01 1.00 0.93, 1.07 0.97
  1. aAdjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)